Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Lenalidomide in Purine Analogue-Failed CLL
NCT00829647Phase 2Withdrawn
- Sponsor
- Scripps Health
- Start
- Jan 2009
- Primary completion
- Dec 2009
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of dasatinib, lenalidomide in chronic lymphocytic leukemia (CLL), sponsored by Scripps Health. Planned start Jan 2009; status: withdrawn.
02
Drugs
dasatiniblenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00829647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00829647.